The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin in a large cohort of German patients with soft tissue and bone sarcomas.

Inclusion Criteria:

• Patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of Trabectedin in any line of therapy.
• Age ≥18years at start of therapy with Trabectedin
• Informed Consent
• Patients already deceased may be included when the treating physician is able to determine the presumptive consent

Exclusion Criteria:

• No follow-up data available

Patients with soft tissue and bone sarcomas treated with Trabectedin